Efficacy, tolerability, and safety of aripiprazole once-monthly versus other long-acting injectable antipsychotic therapies in the maintenance treatment of schizophrenia: a mixed treatment comparison of double-blind randomized clinical trials

BACKGROUND: Treatment with long-acting injectable (LAI) antipsychotic medication is an important element of relapse prevention in schizophrenia. Recently, the intramuscular once-monthly formulation of aripiprazole received marketing approval in Europe and the United States for schizophrenia. OBJECTI...

Descripción completa

Detalles Bibliográficos
Autores principales: Majer, Istvan M., Gaughran, Fiona, Sapin, Christophe, Beillat, Maud, Treur, Maarten
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Co-Action Publishing 2015
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4802697/
https://www.ncbi.nlm.nih.gov/pubmed/27123183
http://dx.doi.org/10.3402/jmahp.v3.27208

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4802697/
https://www.ncbi.nlm.nih.gov/pubmed/27123183
http://dx.doi.org/10.3402/jmahp.v3.27208

Ejemplares similares